Americans pay twice as much as Australians and three times as much as the Dutch for prescription drugs. The disparity in prescription drug costs, with average U.S. per capita spending exceeding $1,000 annually (2020 figures), demands market disruption in essential services.
Brand name prescription drug prices have risen 76% over the past six years (as of 2020), intensifying household financial pressure. Yet, public figures launch ventures proving these essential costs can be significantly lowered, challenging traditional industry models.
Andrew Yang's Noble Mobile, launched last September, exemplifies this trend. It has grown to thousands of customers and generated millions in revenue, according to IndexBox. The growth of Noble Mobile, amid escalating essential costs, creates a significant market opportunity for disruptors. More public figures and mission-driven entrepreneurs will likely enter markets traditionally dominated by large corporations, forcing greater transparency and competition in essential consumer goods and services.
How Do Initiatives Like Cost Plus Drugs Lower Costs?
Mark Cuban's Cost Plus Drug company offers prescription drugs with a fully disclosed price: a 15% markup, a $5 pharmacy service fee, and a $5 shipping fee, according to Forbes. Mark Cuban's Cost Plus Drug company's transparent model directly challenges the pharmaceutical industry's opaque structures.
The company added 1,000 medicines in December, totaling 2,200 drugs offered, Forbes reports. The company's rapid expansion proves the viability of a consumer-focused approach. Drug companies, generating only 23% of healthcare's U.S. revenue, capture 63% of total profits (2020 figures), revealing a market structured for extreme profit extraction.
By offering 2,200 medicines with transparent, low markups, Cost Plus Drug proves that exorbitant prescription drug prices are largely artificial. The offering of 2,200 medicines with transparent, low markups challenges the industry to justify its opaque pricing or face inevitable disruption.
